Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Tikoo, Kulbhushan ^a   Kumar, Parveen ^a   Gupta, Jeena ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CISPLATIN; CREATININE; DIMETHYLBENZ[A]ANTHRACENE; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; HISTONE; SERUM ALBUMIN;

ACETYLATION; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; KIDNEY DISEASE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; KIDNEY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; UDDER;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD UREA NITROGEN; BLOTTING, WESTERN; BODY WEIGHT; CISPLATIN; CREATININE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONES; KIDNEY; KIDNEY DISEASES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; THIAZOLIDINEDIONES; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65749084405     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-107     Document Type: Article

References (43)

1. Jarrar MH Baranova A PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: The importance of interplay with TGFbeta signalling Journal of cellular and molecular medicine 2007, 11(1):71-87 10.1111/j.1582-4934.2007.00003.x
2. Suh N Wang Y Williams CR Risingsong R Gilmer T Willson TM Sporn MB A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis Cancer research 1999, 59(22):5671-5673 10582681
3. Bogdanovic G Kojic V Srdic T Jakimov D Djuran MI Bugarcic ZD Baltic M Baltic VV Growth Effects of Some Platinum(II) Complexes with Sulfur-Containing Carrier Ligands on MCF7 Human Breast Cancer Cell Line upon Simultaneous Administration with Taxol Metal-based drugs 2002, 9(1-2):33-43 2365300 18475423 10.1155/MBD.2002.33
4. Li S Gokden N Okusa MD Bhatt R Portilla D Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF American journal of physiology 2005, 289(2):F469-480 15814532
5. Ali BH Al Moundhri MS Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research Food Chem Toxicol 2006, 44(8):1173-1183 10.1016/ j.fct.2006.01.013 16530908
6. Basnakian AG Apostolov EO Yin X Napirei M Mannherz HG Shah SV Cisplatin nephrotoxicity is mediated by deoxyribonuclease I J Am Soc Nephrol 2005, 16(3):697-702 10.1681/ASN.2004060494 15647342
7. Faubel S Lewis EC Reznikov L Ljubanovic D Hoke TS Somerset H Oh DJ Lu L Klein CL Dinarello CA et al Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney J Pharmacol Exp Ther 2007, 322(1):8-15 10.1124/jpet.107.119792 17400889
8. Lee S Kim W Moon SO Sung MJ Kim DH Kang KP Jang YB Lee JE Jang KY Park SK Rosiglitazone ameliorates cisplatin-induced renal injury in mice Nephrol Dial Transplant 2006, 21(8):2096-2105 10.1093/ndt/gfl194 16728429
9. Ramesh G Reeves WB TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity J Clin Invest 2002, 110(6):835-842 151130 12235115
10. Michalik L Desvergne B Wahli W Peroxisome-proliferator-activated receptors and cancers: Complex stories Nat Rev Cancer 2004, 4(1):61-70 10.1038/nrc1254 14708026
11. Yamaguchi K Lee SH Eling TE Baek SJ A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells Mol Cancer Ther 2006, 5(5):1352-1361 10.1158/1535-7163.MCT-05-0528 16731769
12. Rosen ED Spiegelman BM PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth J Biol Chem 2001, 276(41):37731-37734 11459852
13. Forman BM Tontonoz P Chen J Brun RP Spiegelman BM Evans RM 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 1995, 83(5):803-812 10.1016/ 0092-8674(95)90193-0 8521497
14. Barak Y Nelson MC Ong ES Jones YZ Ruiz-Lozano P Chien KR Koder A Evans RM PPAR gamma is required for placental, cardiac, and adipose tissue development Mol Cell 1999, 4(4):585-595 10.1016/S1097-2765(00)80209-9 10549290
15. Gupta RA Dubois RN Controversy: PPARgamma as a target for treatment of colorectal cancer Am J Physiol Gastrointest Liver Physiol 2002, 283(2):G266-269 12121872
16. Yee LD Young DC Rosol TJ Vanbuskirk AM Clinton SK Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone J Nutr 2005, 135(5):983-988 15867269
17. Jiang C Ting AT Seed B PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 1998, 391(6662):82-86 10.1038/ 34184 9422509
18. Cuzzocrea S Pisano B Dugo L Ianaro A Maffia P Patel NS Di Paola R Ialenti A Genovese T Chatterjee PK et al Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation European journal of pharmacology 2004, 483(1):79-93 10.1016/ j.ejphar.2003.10.056 14709329
19. Varier RA Swaminathan V Balasubramanyam K Kundu TK Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy Biochem Pharmacol 2004, 68(6):1215-1220 10.1016/ j.bcp.2004.05.038 15313419
20. Musri MM Corominola H Casamitjana R Gomis R Parrizas M Histone H3 lysine 4 dimethylation signals the transcriptional competence of the adiponectin promoter in preadipocytes J Biol Chem 2006, 281(25):17180-17188 10.1074/jbc.M601295200 16613853
21. Fu M Wang C Zhang X Pestell RG Acetylation of nuclear receptors in cellular growth and apoptosis Biochem Pharmacol 2004, 68(6):1199-1208 10.1016/j.bcp.2004.05.037 15313417
22. Kurdistani SK Histone modifications as markers of cancer prognosis: A cellular view Br J Cancer 2007, 97(1):1-5 10.1038/sj.bjc.6603844 17592497
23. Mishra SK Mandal M Mazumdar A Kumar R Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells FEBS Lett 2001, 507(1):88-94 10.1016/S0014-5793(01)02951-9 11682064
24. Whitsett T Carpenter M Lamartiniere CA Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats Journal of carcinogenesis 2006, 5:15 1524738 16700914 10.1186/1477-3163-5-15
25. Tikoo K Singh K Kabra D Sharma V Gaikwad A Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy Free Radic Res 2008, 42(4):397-404 10.1080/10715760801998646 18404539
26. Stuhr LE Iversen VV Straume O Maehle BO Reed RK Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors Cancer letters 2004, 210(1):35-40 10.1016/j.canlet.2004.02.012 15172118
27. Tikoo K Tripathi DN Kabra DG Sharma V Gaikwad AB Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53 FEBS Lett 2007, 581(5):1071-1078 10.1016/j.febslet.2007.02.006 17316625
28. Tikoo K Bhatt DK Gaikwad AB Sharma V Kabra DG Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats FEBS Lett 2007, 581(10):2027-2035 10.1016/j.febslet.2007.04.036 17470369
29. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 1991, 19(5):403-410 10.1111/j.1365-2559.1991.tb00229.x 1757079
30. De Zutter GS Davis RJ Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway Proc Natl Acad Sci USA 2001, 98(11):6168-6173 33440 11344273 10.1073/pnas.111027698
31. Cross TG Scheel-Toellner D Henriquez NV Deacon E Salmon M Lord JM Serine/ threonine protein kinases and apoptosis Exp Cell Res 2000, 256(1):34-41 10.1006/excr.2000.4836 10739649
32. Hui L Bakiri L Stepniak E Wagner EF p38alpha: A Suppressor of Cell Proliferation and Tumorigenesis Cell Cycle 2007, 6:20 17957136
33. Liao Y Hung MC Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis Mol Cell Biol 2003, 23(19):6836-6848 193925 12972603 10.1128/MCB.23.19.6836-6848.2003
34. Mueller E Sarraf P Tontonoz P Evans RM Martin KJ Zhang M Fletcher C Singer S Spiegelman BM Terminal differentiation of human breast cancer through PPAR gamma Mol Cell 1998, 1(3):465-470 10.1016/ S1097-2765(00)80047-7 9660931
35. Wang C Pattabiraman N Zhou JN Fu M Sakamaki T Albanese C Li Z Wu K Hulit J Neumeister P et al Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation Mol Cell Biol 2003, 23(17):6159-6173 180960 12917338 10.1128/ MCB.23.17.6159-6173.2003
36. Fu M Wang C Wang J Zafonte BT Lisanti MP Pestell RG Acetylation in hormone signaling and the cell cycle Cytokine & growth factor reviews 2002, 13(3):259-276 10.1016/S1359-6101(02)00003-5 12486878
37. Shibayama Y Kawachi A Onimaru S Tokunaga J Ikeda R Nishida K Kuchiiwa S Nakagawa S Takamura N Motoya T et al Effect of pre-treatment with St John's Wort on nephrotoxicity of cisplatin in rats Life Sci 2007, 81(2):103-108 10.1016/j.lfs.2007.04.025 17543347
38. Mangelsdorf DJ Thummel C Beato M Herrlich P Schutz G Umesono K Blumberg B Kastner P Mark M Chambon P et al The nuclear receptor superfamily: The second decade Cell 1995, 83(6):835-839 10.1016/0092-8674(95)90199-X 8521507
39. Kliewer SA Umesono K Noonan DJ Heyman RA Evans RM Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors Nature 1992, 358(6389):771-774 10.1038/358771a0 1324435
40. Na HK Surh YJ Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation Biochemical pharmacology 2003, 66(8):1381-1391 10.1016/ S0006-2952(03)00488-X 14555212
41. Rubin GL Zhao Y Kalus AM Simpson ER Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy Cancer research 2000, 60(6):1604-1608 10749129
42. Qin C Burghardt R Smith R Wormke M Stewart J Safe S Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells Cancer research 2003, 63(5):958-964 12615709
43. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100(1):57-70 10.1016/S0092-8674(00)81683-9 10647931